Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Alcon Research, Ltd.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Alcon Research, Ltd.

Regulatory records
2
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 2 FDA records to the applicant name Alcon Research, Ltd.. It includes 1 original PMA approval. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Sep 26, 1991 to Oct 1, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code LZP appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P890047, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 6201 S. Fwy., R3-48, Fort Worth, TX, 76134. Recorded on P890047/S072, decision dated Oct 1, 2026.

Changes described in PMA records

P890047/S072: PROVISC Ophthalmic Viscosurgical Device

FDA recorded decision OK30 on 2026-10-01 for supplement S072 to PMA P890047, submitted by Alcon Research, Ltd. The supplement is a 30-Day Notice filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, within the ophthalmic viscosurgical device category (product code LZP, specialty Ophthalmic). The identifier places S072 as a supplement to the existing P890047 PMA rather than a separate original approval.

The reported change is to the Endotoxin testing program for the subject ophthalmic viscosurgical devices (OVDs), including test article preparation and individual component testing. The record does not specify which endotoxin method, limits, sampling plan, components, or supplier site changed, nor does it state an outcome beyond the OK30 decision label. The stated purpose is a testing-program change; the entry gives no independent evidence of safety or clinical performance, and it creates no new indication or approval of the whole device system.

FDA approval-order wording

a change in the Endotoxin testing program for the subject ophthalmic viscosurgical devices (OVDs), including test article preparation and individual component testing

Oct 1, 2026 · 30-Day Notice

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Alcon Research, Ltd.PMA supplementOct 1, 2026FDA
Alcon Research, Ltd.PMA approvalSep 26, 1991FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 19, 2026.